11 results found.

Cushing's Disease,, Acromegaly,, Neuroendocrine Tumors,, Pituitar Clinical Trial using Pasireotide

Novartis - Recruiting 18 years or older.
- An Open Label, Multi-center Pasireotide Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Pasireotide Study and Are Judged by the Investigator to Benefit From Continued Pasireotide Treatment.
Pasireotide

Acromegaly Clinical Trial

Ipsen - Recruiting 18 years or older.
- Description of the Associations of Sign-and-symptom at Acromegaly Diagnosis..

Acromegaly Clinical Trial

University of Aarhus - Recruiting N/A or older.
- Incidence and Late Prognosis of Acromegaly in Denmark From 1991 - 2010: Twenty Years of Medical Treatment.

Acromegaly, Pituitary Gigantism Clinical Trial using SOM230LAR

Novartis - Recruiting 18 years or older.
- A Multicenter, Open-label, Randomized, Phase II Study to Evaluate Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Pasireotide LAR in Japanese Patients With Active Acromegaly or Pituitary Gigantism.
SOM230LAR

Acromegaly, Somatostatin, Metabolism, or Signal Transduction Clinical Trial using GH

University of Aarhus - Recruiting 18 years or older.
- Somatostatin Analogue Treatment of Acromegaly: Molecular Aspects.
GH

Acromegaly Clinical Trial

Massachusetts General Hospital - Recruiting 18 years to 75 years.
- Effect of Growth Hormone Receptor Antagonism and Somatostatin Analog Administration on Quality of Life.

Acromegaly Clinical Trial

Massachusetts General Hospital - Recruiting 18 years to 75 years.
- Ectopic Lipid Deposition and Insulin Resistance in After Treatment of Acromegaly.

Acromegaly, or Pituitary Neoplasm Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- Acromegaly Treatment and Natural History.

Acromegaly Clinical Trial

TC Erciyes University - Recruiting 18 years or older.
- Investigation of Prevalence and Clinical Effects of Aryl Hydrocarbon Receptor Interacting Protein (AIP) Gene Mutations With DNA Sequence Analysis in Acromegaly Patients in Turkey.

Acromegaly Clinical Trial using Sandostatin LAR

Cedars-Sinai Medical Center - Recruiting 18 years or older.
- Does Ultrasound-Guidance Improve the Delivery and Efficacy of Intramuscular (IM) Injection of Sandostatin LAR in the Treatment of Acromegaly.
Sandostatin LAR

Acromegaly Clinical Trial

National Center for Research Resources (NCRR) - Recruiting 20 years to 75 years.
- .